CDA GMBH

Their core work

CDA GmbH is a German technology SME specializing in photonics and optical systems, with applied expertise spanning medical diagnostics and precision laser manufacturing. In PHOCNOSIS, they contributed to developing nanophotonic point-of-care devices for rapid cardiovascular biomarker detection — work that sits at the intersection of optical engineering and clinical instrumentation. In PHENOMENON, they worked on laser-based fabrication of 3D nanostructured optical components using advanced photochemistry. Their core competence appears to be translating photonic and optical principles into functional hardware, whether for diagnostics or precision manufacturing.

What they specialise in

How they've shifted over time

CDA's two projects run nearly back-to-back (2015–2021) and both sit within photonics, but they represent a shift in application domain. Their first project, PHOCNOSIS, applied nanophotonic technology to health — specifically cardiovascular point-of-care diagnostics, where the end output is a clinical device. Their second project, PHENOMENON, redirected the same photonic expertise toward manufacturing — using lasers and photochemistry to produce nanostructured optical components. The trajectory suggests CDA is moving from photonics-for-diagnostics toward photonics-for-production, potentially positioning as a supplier of optical components or laser processing capability rather than a medical device integrator.

CDA appears to be pivoting from health-facing optical instrumentation toward industrial photonic manufacturing, which suggests future collaborations in precision optics production, photonic component supply chains, or laser-based micro/nanofabrication are more likely than medical device projects.

How they like to work

CDA participates exclusively as a consortium partner — they have never led an H2020 project — which positions them as a specialist contributor rather than a project orchestrator. With 23 unique partners across just 2 projects, they work within mid-to-large consortia (roughly 10+ partners per project), suggesting they are comfortable operating as one node in a complex multi-partner structure. The diversity of partners and countries (8) with no apparent repetition implies they bring specific technical capability that different consortia seek out, rather than building a tight long-term network with recurring collaborators.

CDA has accumulated 23 unique consortium partners across 8 countries from just two projects, indicating they join internationally diverse consortia. No geographic concentration is discernible from the available data, but their German base and European project participation suggest a primarily European network.

What sets them apart

CDA is a rare SME that bridges two distinct photonics application domains — biomedical diagnostics and advanced manufacturing — within the same technical competence base. Operating from Suhl in Thuringia, a region with deep precision engineering heritage, they likely combine optical systems know-how with practical fabrication and integration capacity that larger research institutes may lack. For consortium builders, they offer the credibility of an industrial partner with genuine photonics depth, without the overhead of a large company.

Highlights from their portfolio

• PHOCNOSIS
  Largest funding award (EUR 336,538) and the clearest demonstration of CDA's ability to apply nanophotonics to a high-stakes clinical problem — rapid cardiovascular disease diagnosis.
• PHENOMENON
  Marks CDA's expansion into laser-based nanofabrication, combining photochemistry and 3D nanostructuring — an unusual capability pairing that signals cross-sector potential.